The effect of adjuvant treatment in obsessive compulsive disorder patients: A systematic review and meta-analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 41624657.
- Also identified by DOI 10.4103/jfmpc.jfmpc_281_25 and PMC identifier 12858126.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Obsessive-compulsive disorder (OCD) is a neuropsychiatric condition characterized by the presence of intrusive thoughts, referred to as obsessions, and repetitive behaviors, known as compulsions. Globally, OCD affects approximately 2-3% of the population. Three databases (PubMed, Web of Science, and MEDLINE) were explored for the present study, from January 1, 2000 to December 31, 2024. The analysis was conducted using R version 4.3.2 to estimate the overall treatment effect of memantine and risperidone for OCD, relative to placebo, via meta-analysis. The Pooled Standardized Mean Differences (SMDs) were computed using both fixed-effect and random-effects models. Only 10 studies were included in current investigation, after identification of 2362 articles. Meta-analysis of memantine suggested statistically insignificant (<i>P</i> value = 0.06) reduction in Y-BOCS score [SMD: -1.02 (-2.12, 0.08)], whereas meta-analysis of risperidone suggested statistically significant (<i>P</i> value = 0.03) reduction in Y-BOCS score [SMD: -0.38 (-0.74, -0.02)]. Risperidone plays a significant role in reduction of Y-BOCS score in OCD patients, whereas memantine does not show a significant effect in reducing the Y-BOCS score in OCD patients.